SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-23-233934
Filing Date
2023-09-13
Accepted
2023-09-13 08:00:29
Documents
13
Period of Report
2023-09-13
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d545132d8k.htm   iXBRL 8-K 25239
2 EX-99.1 d545132dex991.htm EX-99.1 9917
  Complete submission text file 0001193125-23-233934.txt   164832

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA antx-20230913.xsd EX-101.SCH 2874
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE antx-20230913_lab.xml EX-101.LAB 18737
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE antx-20230913_pre.xml EX-101.PRE 11723
7 EXTRACTED XBRL INSTANCE DOCUMENT d545132d8k_htm.xml XML 3460
Mailing Address 1800 EL CAMINO REAL, SUITE D MENLO PARK CA 94027
Business Address 1800 EL CAMINO REAL, SUITE D MENLO PARK CA 94027 (650) 331-9090
AN2 Therapeutics, Inc. (Filer) CIK: 0001880438 (see all company filings)

IRS No.: 820606654 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41331 | Film No.: 231251634
SIC: 2834 Pharmaceutical Preparations